Supply Vonoprazan Fumarate and Related Intermediate
5-(2-Fluorophenyl)pyrrole-3-Carboxaldehyde CAS 881674-56-2
Pyridine-3-Sulfonyl Chloride CAS 16133-25-8
Vonoprazan Fumarate (TAK-438) CAS 1260141-27-2 881681-01-2
| Chemical Name | Pyridine-3-Sulfonyl Chloride |
| Synonyms | 3-Pyridinesulfonyl Chloride; 3-Pyridylsulfonyl Chloride; m-Pyridinesulfonyl Chloride; Piperidine-3-Sulfonylchloride |
| CAS Number | 16133-25-8 |
| CAT Number | RF-PI540 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C5H4ClNO2S |
| Molecular Weight | 177.61 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | Colorless or Pale Yellow Liquid |
| Purity / Analysis Method | ≥98.5% (GC) |
| Boiling Point | 110.0~112.0℃/2mm Hg |
| Single Impurity | ≤0.50% |
| Total Impurities | ≤1.5% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Vonoprazan Fumarate (CAS: 1260141-27-2) |
Package: Bottle, 25kg/Barrel, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
Pyridine-3-Sulfonyl Chloride (CAS: 16133-25-8) is an intermediate of Vonoprazan Fumarate (CAS: 1260141-27-2). Vonoprazan Fumarate, discovered and developed by Takeda and Otsuka, was approved by the PMDA of Japan in December 2014, and is indicated for the treatment of gastric ulcer, duodenal ulcer and reflux esophagitis. Vonoprazan fumarate has a novel mechanism of action called potassium-competitive acid blockers, which competitively inhibit the binding of potassium ions to H+, K+-ATPase (also known as the proton pump) in the final step of gastric acid secretion in gastric parietal cells. Vonoprazan does not inhibit Na+, K+-ATPase activity even at concentrations 500 times higher than that of their IC50 values against gastric H+, K+-ATPase activity. Furthermore, the drug is unaffected by the gastric secretory state, unlike PPIs.